IL194942A0 - PHARMACEUTICAL COMPOSITIONS COMPRISING CBx CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS - Google Patents

PHARMACEUTICAL COMPOSITIONS COMPRISING CBx CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS

Info

Publication number
IL194942A0
IL194942A0 IL194942A IL19494208A IL194942A0 IL 194942 A0 IL194942 A0 IL 194942A0 IL 194942 A IL194942 A IL 194942A IL 19494208 A IL19494208 A IL 19494208A IL 194942 A0 IL194942 A0 IL 194942A0
Authority
IL
Israel
Prior art keywords
modulators
cbx
pharmaceutical compositions
potassium channel
cannabinoid receptor
Prior art date
Application number
IL194942A
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of IL194942A0 publication Critical patent/IL194942A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
IL194942A 2006-04-27 2008-10-27 PHARMACEUTICAL COMPOSITIONS COMPRISING CBx CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS IL194942A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06113188 2006-04-27
PCT/EP2007/053914 WO2007125048A1 (en) 2006-04-27 2007-04-20 Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators

Publications (1)

Publication Number Publication Date
IL194942A0 true IL194942A0 (en) 2009-08-03

Family

ID=37022868

Family Applications (1)

Application Number Title Priority Date Filing Date
IL194942A IL194942A0 (en) 2006-04-27 2008-10-27 PHARMACEUTICAL COMPOSITIONS COMPRISING CBx CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS

Country Status (13)

Country Link
EP (1) EP2026798A1 (en)
JP (1) JP2009534439A (en)
KR (1) KR20090007606A (en)
CN (1) CN101431998A (en)
AR (1) AR060625A1 (en)
AU (1) AU2007245733A1 (en)
BR (1) BRPI0711064A2 (en)
CA (1) CA2650566A1 (en)
EA (1) EA200802132A1 (en)
IL (1) IL194942A0 (en)
MX (1) MX2008013678A (en)
TW (1) TW200808785A (en)
WO (1) WO2007125048A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009269869A (en) * 2008-05-09 2009-11-19 Japan Health Science Foundation New use of cannabinoid receptor agonist
WO2013140342A1 (en) * 2012-03-19 2013-09-26 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
WO2014208939A1 (en) * 2013-06-28 2014-12-31 Hanmi Pharm. Co., Ltd. 1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives as cannabinoid cb1 receptor antagonist, method for preparing same, and pharmaceutical composition comprising same
CN106138053B (en) * 2015-04-28 2019-04-09 上海市同济医院 A kind of application of compound in the drug of preparation treatment Parkinson's disease
US20190060300A1 (en) * 2016-03-04 2019-02-28 Sharon Anavi-Goffer Self-Emulsifying Compositions of CB2 Receptor Modulators
TWI805699B (en) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 Methyllactam ring compound and pharmaceutical use thereof
WO2020123250A1 (en) * 2018-12-11 2020-06-18 John Heaney Cannabinoid derivatives and methods for their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742148B1 (en) * 1995-12-08 1999-10-22 Sanofi Sa NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for the peripheral cannabinoid receptor
UA74367C2 (en) * 2000-03-23 2005-12-15 Сольве Фармас'Ютікалз Б.В. DERIVATIVES OF 4,5-DIHYDRO-1Н-PYRAZOLE, REVEALING ANTAGONISTIC ACTIVITY RELATIVE TO СВ<sub>1, A METHOD FOR PRODUCING THEREOF, PHARMACEUTICAL COMPOSITION AND A METHOD FOR PRODUCING THEREOF, A METHOD FOR THE TREATMENT OF DISEASES (VARIANTS)
ES2229132T3 (en) * 2001-03-22 2005-04-16 Solvay Pharmaceuticals B.V. DERIVATIVES OF 4,5-DIHIDRO-1H-PIRAZOL THAT HAVE ACTIVITY AS AN ANCHANGIST OF CB1.
AR038966A1 (en) * 2002-03-18 2005-02-02 Solvay Pharm Bv DERIVATIVES OF TIAZOL THAT HAVE ANTAGONIST, AGONIST OR PARTIAL AGONIST ACTIVITY OF CB1
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
TWI336697B (en) * 2003-09-19 2011-02-01 Solvay Pharm Bv Thiazole derivatives as cannabinoid receptor modulators
AU2005298692A1 (en) * 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions

Also Published As

Publication number Publication date
BRPI0711064A2 (en) 2011-08-23
MX2008013678A (en) 2008-11-04
WO2007125048A1 (en) 2007-11-08
CN101431998A (en) 2009-05-13
EP2026798A1 (en) 2009-02-25
JP2009534439A (en) 2009-09-24
CA2650566A1 (en) 2007-11-08
TW200808785A (en) 2008-02-16
AR060625A1 (en) 2008-07-02
KR20090007606A (en) 2009-01-19
EA200802132A1 (en) 2009-06-30
AU2007245733A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
HUS1500065I1 (en) Compounds and compositions as hedgehog pathway modulators
IL192613A (en) Cycloalkylamines and pharmaceutical compositions comprising same
IL242883B (en) Arylamino- and heteroarylamino-substituted dioxoazolines and pharmaceutical compositions comprising them
AU2013257508A1 (en) Pharmaceutical compositions
EP2001498A4 (en) Pharmaceutical compositions
IL194176A0 (en) Pharmaceutical compositions
GB0713625D0 (en) Pharmaceutical compositions
EP2061465A4 (en) Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
HK1138181A1 (en) Immune modulators, compositions including immune modulators and use thereof
HK1138732A1 (en) Pharmaceutical compositions
GB0625196D0 (en) Modulators of cannabinoid receptor
IL196814A0 (en) Modulators of glucocorticoid receptors, ap-1, and/or nf-kb and uses thereof
IL198990A0 (en) Cb1 receptor modulators
IL194942A0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING CBx CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS
EP2022362A4 (en) Viscous cosmetic
IL197107A0 (en) Pharmaceutical compositions including vitamin d and corticosteriod
EP1985658A4 (en) Hydrogenated nbr compositions
IL198648A (en) Triazinedione derivatives as gaba-b receptor modulators, pharmaceutical compositions comprising them and their uses
HK1135617A1 (en) Shampoo composition
GB0614365D0 (en) Pharmaceutical compositions and their use
GB0622569D0 (en) Cannabinoid receptor modulators
EP2124959A4 (en) Pharmaceutical composition
ZA200806237B (en) Cannibinoid receptor modulators
GB0625197D0 (en) Cannabinoid receptor modulators
IL178937A0 (en) Pharmaceutical and cosmetic compositions